anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention provides a system for treating heart disease as a 'bridge to recovery' using cellular cardiomyoplasty. The system is particularly useful in selecting and treating patients with damaged myocardium due coronary artery disease, myocardial infarction, congestive heart failure, and ischemia. Based on various clinical criteria, a patient is selected and optionally treated using cellular cardiomyoplasty to improve the patient's cardiac function. The cardiomyoplasty may be combined with other treatments such as medications or left ventricular assist devices. Preferably, the cellular cardiomyoplasty eliminates the need for invasive surgery such as by-pass grafting or cardiac transplantation. The invention also provides kits for use in selecting and treating patients using the inventive method.
INTRODUCTION: There are many criteria for diagnosing Guillain-Barré syndrome (GBS), and the yield of these diagnostic criteria varies. Each criterion requires some laboratory data and nerve conduction studies (NCS). Although supportive laboratory data are reassuring when present in suspected cases of GBS, when absent, they can potentially cause further delay in diagnosis and treatment. There is no gold standard test for the diagnosis of GBS, and there are multiple diagnostic criteria for GBS to date. The aim of the study is to know the sensitivity of different criteria, clinical and electrophysiological, for the diagnosis of GBS and to study the clinical spectrum and electrophysiological spectrum of GBS in our cohort of patients.
MATERIALS AND METHODS: We studied a total of 43 cases who presented with one or more of the following symptoms: relatively symmetrical and progressive flail-type weakness of more than one limb, with or without ataxia and/or ophthalmoplegia, and were diagnosed with GBS according to clinical criteria at the time of admission to Government Stanley Medical College Hospital. GBS mimics were ruled out. In all patients, the demographic data, cerebrospinal fluid (CSF) analysis (if done), and electrophysiological findings fitting into the diagnostic criteria of National Institute of Neurological Disorders and Stroke (NINDS), Dutch, and Brighton criteria were recorded. The need for assisted mechanical ventilation, neurology intensive care unit (NICU) stay, any complications, and treatment outcome details were recorded in a structured proforma.
RESULTS: Most of the patients in our study were in their fourth decade of life, with a mean age of 41.37 years, similar to previous studies from India. Men are more frequently affected compared to women, similar to what has been observed in most studies done previously worldwide. In our study, electrophysiological criteria by Dutch criteria (87.5%), Brighton criteria (87.5%), and NINDS criteria (85.6%) had low sensitivity compared to the clinical criteria.
CONCLUSION: In the present study, electrophysiological criteria proposed by the NINDS, Dutch, and Brighton criteria are less sensitive compared to clinical criteria in diagnosing GBS at early stages. Clinical criteria alone may be useful in resource-poor countries and at peripheral healthcare systems where NCS are not always readily available.
The invention discloses a novel acyclic nucleoside compound with a general formula structure shown as the specification and significant anti-tumor activity, a synthetic method and application thereof in research and development of anti-tumor drugs, belonging to the technical field of pharmaceutical chemistry. The invention also discloses the application of the compound, the pharmaceutical salt thereof and the compound medicine thereof in preparing medicines for preventing or treating diseases related to tumors. The invention synthesizes a series of acyclic nucleoside compounds with different substituents at the position 2/6/8 of purine and the position 1' of a purine side chain through the reaction of aza Michael addition reaction, allylic amination reaction and the like, and the compounds comprise racemates, R-configuration and S-configuration, and have the general structure (. is a chiral center). The compound or the pharmaceutically acceptable salt thereof provided by the invention can effectively inhibit the growth of tumor cells in vitro and in vivo, and can be applied to preparationPreparing a medicament for preventing or treating diseases related to tumors. The tumor-related diseases include benign and malignant tumors and other diseases caused by tumors.
People between the ages of 30-75 ,with no previous heart attack or stroke history, who have been diagnosed with high blood pressure, who are either taking medication for high blood pressure for 2 years or less; or have discussed managing high blood pressure in the past 2 years. These people will see items only pertaining to high blood pressure.
Stroke is the second-leading cause of death and also a leading cause of combined death and disability. In Bangladesh, stroke prevalence is 11.39 per 1000 population, but highest prevalence of stroke is 14.71 per 1000 population in the Mymensingh division. Hyperuricemia has been reported as an independent risk factor for stroke in different studies and a significant association between serum uric acid and dyslipidemia has also been stated. On the contrary, some studies suggest that uric acid has a neuroprotective role. This cross-sectional study was completed in the Medicine Department of Mymensingh Medical College Hospital, Mymensingh, Bangladesh from March 2021 to January 2023. In this cross-sectional study, 352 adult acute ischemic stroke patients were included from the Medicine Department of Mymensingh Medical College Hospital. Serum uric acid and fasting serum lipid levels were measured within 48 hours of admission. The mean age ±SD of the respondents was 61.9±12.8 years. Hyperuricemia was found among 18.2% of respondents, whose mean ±SD serum uric acid was 5.7±1.9 mg/dl. Dyslipidemia was present in 88.4% of patients. The mean ±SD of the National Institutes of Health Stroke Scale (NIHSS) score was 12.0±5.9. Most of the patients (65.6%) were suffering from moderate stroke, followed by moderate to severe stroke (15.1%), severe stroke (10.8%) and minor stroke (8.5%). After multiple linear regressions, the independent variables age, gender, serum uric acid and total cholesterol were found to be significant predictors of the NIHSS score of the respondents. In conclusion, the majority of acute ischemic stroke patients have an association with dyslipidemia, but only around one-fifth of patients have hyperuricemia. There is a significant association of high serum uric acid and high serum total cholesterol with stroke severity (NIHSS score). But low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and, triglycerides have no association with stroke severity.
The purpose of this study is to determine the efficacy of the probiotic B. subtilis DE111® for regulation of bowel movements. A single capsule containing 1 x 10\^9 CFU B. subtilis is to be consumed once a day per participant. 50 adults (18-65 years of age at the time of participation) suffering from occasional constipation and/or diarrhea will be enrolled. Participants will be double-blindly and randomly assigned to either the probiotic (Bacillus subtilis) or the placebo (maltodextrin) group. Efficacy will be assessed with participant-reported bowel movement (BM) records. As a secondary outcome, the study will provide further insight into the tolerance of the supplement. Tolerance will be assessed using a digestive health questionnaire and blood samples to analyze pertinent metabolic biomarkers. Participants will be asked to complete a daily dietary intake record as well. Prior to capsule consumption, participants will complete a two-week pre-testing phase in order to provide a more inclusive diagnostic baseline. This phase will consist of daily BM and dietary intake record keeping.
The Surgical Treatments Outcomes Project for Dysfunctional Uterine Bleeding (STOP-DUB) is a multicenter, randomized clinical trial that assessed the efficacy and effectiveness of hysterectomy versus endometrial ablation (EA) for dysfunctional uterine bleeding (DUB) in women for whom medical management has not provided relief. Institutional review board-approved study sites included the coordinating center, chair's office, the American College of Obstetricians and Gynecologists, and 33 clinical centers in the United States and Canada. STOP-DUB enrolled (1) 237 eligible patients for whom medical treatment had not been successful and who were randomized to either hysterectomy or EA; and (2) an observational cohort of 139 patients who were "provisionally ineligible" or who were eligible but did not wish to be randomized. Enrollment began November 25, 1997 and ended June 30, 2001. Randomized women were followed using telephone interviews at least 2 years and observational women were followed a maximum of 6 months. We also collected information on return clinical center visits and hospital bills from the sites directly. The primary outcome addressed by the randomized trial is the impact of surgery on bleeding, pain, fatigue, and the major problem (symptom) that led the woman to seek treatment for her condition, measured 1 year following surgery. Additional outcomes included the impact of surgery at time points after 1 year; changes in quality of life, activity limitation, sexual functioning, and urinary incontinence; surgical complications; additional surgery; and resource utilization. The costs and the relative cost-effectiveness of the two surgeries will be calculated. The main scientific objective for the observational study was to examine changes over time in terms of treatment selected, DUB-related symptoms, and quality of life. Enrolled women signed an informed consent to participate.
PURPOSE:To improve reading efficiency by judging the frequency of a picture to by stored by collated with judgement reference and storing it in the optimum recording medium. CONSTITUTION:In a CPU8, the judgement reference to judge the frequency of the picture to be stored in respective storage mediums according to the request of a user is set in advance. The CPU8 judges the picture with high frequency of utilization while observing the additional data for newest inspection and collating the judgement reference preliminarily stored in a memory 8M. Next, when the user inputs a picture ID from a touch panel 12 to perform reading, a control signal based on this interrupts to the CPU8, and the CPU8 takes the ID information in a register. Then, it retrieves the corresponding list. Thus, the required picture is displayed on a display 7 through a MDS9, and the reading of the required picture can be performed.
PURPOSE: A skin external formulation composition containing shell and calcium strong alkali solution waste coral is provided to prevent and treat dermatitis and relieve pruritus and wrinkle. CONSTITUTION: A skin external formulation composition contains alkali calcium solution extracted from shell. A skin external formulation contains 0.3-20 weight parts of safflower based on 100 weight parts of carrier having alkali calcium solution. The composition further contains 0.5-30 weight parts of medicinal herb extract. The composition additionally contains 0.3-15 weight parts of rucinol, 0.3-15 weight parts of terrane or 0.2-5 weight parts of coenzyme Q10. The composition also contains 0.05-5 weight parts of vitamin C as a calcium absorption promoter.
Sensorimotor exercise group; oculomotor exercise to provide information from the visual system, laser target exercise to provide information from the proprioception system, and postural stability exercise to provide information from the vestibular system. Within the scope of oculomotor exercise, gaze stability exercise and head-body coordination exercise will be given to the participants. Laser target exercise will be given with the laser target fixed on the participant's head and 90 cm away from the target. Postural stability exercise will be given in the form of tandem exercise and standing on one leg.
PURPOSE: Olfactory training (OT) is an effective and affordable option in the treatment of olfactory dysfunction. Despite significant progress in the field in recent years, some factors influencing OT participation remain unclear.
METHODS: Based on an anonymous online survey orchestrated by AbScent.org the present study enrolled 450 participants and divided them into OT (n = 161) and No OT (n = 289) groups based on their OT participation. Participants also provided information on demographics, medical history, quality of life, OT duration for those who engaged in OT, and the reasons for non-participation in OT among those who did not.
RESULTS: Patients who had greater loss of quality of life participated more in OT. Similarly, more participation was observed in patients who noticed an improvement in their ability to smell. Notably, most of the sample engaged in OT trained less than four weeks (73%). In the No OT group, the primary barrier to OT participation was the unawareness of OT treatment (37%) and these barriers differed by age, where older people expressed interest but were unaware of OT treatment, while younger individuals exhibited more cautiousness about its effectiveness.
CONCLUSION: Lower quality of life drives active OT participation. Limited training periods and unawareness of OT serve as potential barriers to olfactory recovery. Clinicians should actively promote the background of OT and underscore the significance of adhering to the "prescribed" training regimen.
FIELD: medicine, dermatology, pharmacy. SUBSTANCE: invention relates to the development of new medicinal agents used for treatment of psoriasis. Invention represents the composition for topical application comprising spirituous extract obtained from human placenta as an active component. This extract consists of unsaturated fatty acids, such as palmitoleic and oleic acids, and polyunsaturated fatty acids, such as linoleic, arachidonic and eicosatrienoic acids, and water-soluble excipient. In particular, 100 g of composition can comprise about 59 ml of this spirituous extract in water-soluble excipient. The composition represents water-soluble gel. The composition elicits the expressed an anti-psoriatic effect and absence of undesirable adverse effects. EFFECT: valuable medicinal properties of composition. 3 cl, 2 dwg, 9 ex
This is a prospective, multicenter, open label study of the safety and effectiveness of ORBERA365™ for use as an adjunct to behavioral modification for obese adults (BMI ≥ 27 kg/m2 and BMI ≤ 50 kg/m2) or for pre-surgical weight reduction in obese and super-obese adults (BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with comorbidities). All study subjects will participate in a behavioral modification program for 52 weeks, which will include a low calorie diet as well as nutritional and behavior modification counseling. Subjects will have ORBERA365™ placed for up to 52 weeks.

Evaluations while on treatment will be performed at baseline (pre-placement), Day 0 (ORBERA365 placement) and during monthly clinic visits during the 1st 6 months of device therapy and at months 9 and ORBERA365 removal. All subjects will have a final study visit at 12 months, or study exit, whichever comes first. Device removal will occur at 52 unless removed early by subject request and/or physician recommendation. Reasons for early removal may include, but are not limited to, adverse events, subject dissatisfaction or achievement of weight loss goal.
The first study cohort will receive 60 mg/m2 of paclitaxel on cycle days 1, 8, and 15 as a 1 hr infusion. Immediately following paclitaxel, 30 mg/m2 irinotecan will be administered as a 90 minute intravenous infusion. Irinotecan doses will be administered in an identical infusion schedule on days 8 and 15 of each treatment cycle.
PCT No. PCT/US97/08865 Sec. 371 Date Nov. 26, 1999 Sec. 102(e) Date Nov. 26, 1999 PCT Filed May 22, 1997 PCT Pub. No. WO97/44024 PCT Pub. Date Nov. 27, 1997The present invention provides methods and products for inhibiting neutrophil adhesion and neutrophil aggregation. The invention includes a method for treating a subject to inhibit neutrophil adhesion and neutrophil aggregation by administering 16-hydroxyeicosatetraenoic acid (16-HETE) to the subject. 16-HETE is an arachidonic acid metabolite. The invention also includes a pharmaceutical preparation of 16-HETE. Methods and products are also provided for treating thromboembolic stroke. The method involves the administration of 16-HETE in combination with a thrombolytic agent to a patient suffering from thromboembolic stroke. Preferably, the 16-HETE is 16(R)-HETE and the thrombolytic agent is tPA. The product is a pharmaceutical preparation of 16-HETE and a thrombolytic agent and a pharmaceutically acceptable carrier.
Sildenafil citrate, 75 mg daily divided in 3 doses. From third to 14th day after subarachnoid hemorrhage.
Cigarette smoking is a significant risk factor for coronary artery disease. However, there is insufficient evidence regarding the long-term clinical effects of smoking in Asian populations with chronic total occlusion (CTO). This study aimed to assess the effects of smoking on 5-year (median follow-up period, 4.2 ± 1.5 [interquartile range, 4.06-5.0] years) clinical outcomes in patients with CTO lesions who underwent percutaneous coronary intervention (PCI) or medical treatment (MT). We enrolled 681 consecutive patients with CTO who underwent diagnostic coronary angiography and subsequent PCI or MT. The patients were categorized into smokers (n = 304) and nonsmokers (n = 377). The primary endpoint was major adverse cardiovascular events (MACE), including a composite of all-cause death, myocardial infarction, and revascularization over a 5-year period. Propensity score matching (PSM) analysis was performed to adjust for potential baseline confounders. After PSM analysis, two propensity-matched groups (200 pairs, n = 400) were generated, and the baseline characteristics of both groups were balanced. The smokers exhibited a higher cardiovascular risk of MACE (29.5% vs. 18.5%, p = 0.010) and non-TVR (17.5 vs. 10.5%, p = 0.044) than the nonsmokers. In a landmark analysis using Kaplan-Meier curves at 1 year, the smokers had a significantly higher rate of MACE in the early period (up to 1 year) (18.8% and 9.2%, respectively; p = 0.008) compared with the nonsmokers. The Cox hazard regression analysis with propensity score adjustment revealed that smoking was independently associated with an increased risk of MACE. These findings indicate that smoking is a strong cardiovascular risk factor in patients with CTO, regardless of the treatment strategy (PCI or MT). In addition, in the subgroup analysis, the risk of MACE was most prominently elevated in the group of smokers who underwent PCI.
FIELD: biotechnology. SUBSTANCE: invention relates to preparing biologically active substances from plant raw. Method involves preparing juice from fresh leaves of plants of genus Serratula which is filtered. Filtrate is concentrated by evaporation or water freezing out and formed ice is removed. EFFECT: simplified process, increased output and yield of product, decreased consumption of reagents and energy. 2 ex
According to the Hong Kong Census and Statistic Department, 10.5% of the Hong Kong population who aged 15 years or above are daily smokers (Thematic Household Survey Report - Report No. 59, 2016). The smoking prevalence was estimated from a thematic household survey that has been conducted every 2 or 3 years. Another population-based survey related to tobacco control is the Tobacco Control Policy-related Survey conducted by the Hong Kong Council on Smoking and Health and the University of Hong Kong. Both surveys were in a cross-sectional design and no follow-up was done. A cohort study with follow-up data could provide more insights for the causal relationship. However, most people are not willing to complete follow-up survey and the response rate is often low (Mellahi, 2016). The low survey response rate could lead to statistically bias in the research funding (Pit, 2014). Therefore, cohort surveys need to provide attractive monetary incentive to the interviewee to increase the response rate (Pit, 2014).

This study aims to assess and compare the 3-month response rate of a follow-up survey due to different financial incentive schemes. The findings will be used for a feasibility assessment of future cohort studies of evaluating tobacco control measures and public opinion, and exploration of appropriate incentive scheme.
Unconjugated hyperbilirubinemia in Crigler-Najjar (CN) disease is conventionally treated with phototherapy and/or phenobarbital. Life-long daily phototherapy has considerable disadvantages. Main problems are a decreasing efficacy with age and a profound impact of the intensive phototherapy regimen on the quality of (social) life. An alternative treatment option for unconjugated hyperbilirubinemia is based on intestinal capture of UCB by oral treatment. Particularly when plasma UCB concentrations are high as in CN disease, UCB can diffuse from the blood into the intestinal lumen across the mucosa. Intestinal capture of UCB followed by fecal excretion reduces the enterohepatic circulation of UCB and subsequently decreases plasma UCB concentration. We demonstrated in Gunn rats, the animal model for CN disease, that orlistat treatment decreases plasma UCB concentrations parallel with increased fecal fat excretion, and induces net transmucosal excretion of UCB from the blood into the intestinal lumen. In human adults, orlistat has been widely applied for treatment of obesity, without serious side effects. Recent studies in obese adolescents and prepubertal children indicate that short-term orlistat treatment is well-tolerated by children and generally has only mild side effects. In the present randomized, placebo-controlled trial we determined in patients with CN disease the effects of orlistat treatment on plasma UCB concentrations, and on fecal excretion of fat and UCB.
A process for the preparation of large-ring cyclodextrins (LR-CD) with a degree of polymerisation (DP) of 9 - 21 from starch is described. LR-CD are obtained in a biocatalytic process in high yields by controlling the temperature and reaction time. The LR-CD mixtures obtained arc separated from glucose and others reaction products in a precipitation process. After removal of smaller CD by complexation reactions enhanced by an ultrasonication treatment, CD 9  to CD 21  can then be obtained in high purity following separation by preparative liquid chromatography on a combination of reversed (ODS, octadecyl silicate) and amino phases. Smaller CD, in particular CD 6 , CD 7  and CD 8 , (α-, (β-, and γ-cyclodextrin) and their derivatives are already produced commercially in large scale. In contrast, owing to the low yields in previously described production processes and the difficulties in their isolation, it has been not possible to obtain LR-CD in any larger amounts. The invention allows the preparation of single LR-CD in pure form obtained in high yields in a biocatalytic process.
FIELD: medicine; oncology; immunology.SUBSTANCE: group of inventions is intended for eliciting an immune response to an antigen, such as antigens of malignant tumors and microorganisms. Device for modulating the immune response contains a framework composition containing mesoporous silica rods. Said framework composition has a polyethyleneimine (PEI) modified surface. Said framework composition contains open interconnected macropores or is a pore-forming framework composition. In another embodiment, a method of treating a malignant tumor in a subject in need thereof is disclosed, involving the introduction of said device. Also disclosed is a method of increasing immunogenicity of antigen, involving combining antigen with PEI in said device.EFFECT: use of the group of inventions enables to increase the antigen immunogenicity.29 cl, 35 dwg, 4 tbl, 2 ex